In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in €25mm for Pieris AG

Executive Summary

New investors OrbiMed Advisors and Novo Nordisk Biotech Fund led Pieris AG's (developing Anticalins, a class of proteins used in the diagnosis and treatment of diseases) €25mm ($38mm) Series B venture round. All returning shareholders, including Global Life Science Ventures, Gilde Healthcare Partners, and Forbion Capital Partners also participated. A member of OrbiMed will take a seat on the company's board.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies